StockNews.AI
NTRB
StockNews.AI
20 hrs

Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000

1. Nutriband raised $5.3M from warrants at $6.43 exercise price. 2. Funds will support AVERSA Fentanyl's clinical development and FDA submission. 3. AVERSA Fentanyl could achieve $80M to $200M in peak annual sales. 4. Nutriband is focused on abuse-deterrent pharmaceutical product development. 5. The company faces risks regarding product approval and market conditions.

5m saved
Insight
Article

FAQ

Why Bullish?

The exercised warrants injecting $5.3M will fund crucial development, enhancing NTRB’s growth prospects. Previous examples, such as successful funding rounds in biotech, often lead to positive stock reactions.

How important is it?

This funding news is vital as it will directly influence NTRB's ability to finalize critical product developments, which are key to its market strategy and potential financial growth.

Why Long Term?

The outcomes of the clinical developments and FDA submissions will take time to materialize, influencing available capital and strategic positioning over the longer horizon.

Related Companies

ABUSPFEJNJ
ORLANDO, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of abuse deterrent pharmaceutical products announced today that it has seen warrants exercised at a strike price of $6.43 for proceeds to the company of $5,306,000. The primary use of proceeds will be used towards the remaining clinical development of AVERSA Fentanyl and submission of its NDA with the FDA for marketing approval. AVERSA Fentanyl has the potential to become the world's first opioid patch with abuse deterrent properties and is estimated it could reach peak annual US sales of $80 million to $200 million.1 1 Health Advances Aversa Fentanyl market analysis report 2022 About Nutriband Inc.We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release. Forward-Looking StatementsCertain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof. Contact Information:Nutriband Inc.Phone: 407-377-6695Email: info@nutriband.comSOURCE: Nutriband Inc.

Related News